[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649490":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":45,"collaborators":23,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":23,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":23,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":23,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Fu Jen Catholic University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1 not stop for 1 week","PLACEBO_COMPARATOR","GLP-1 stop for 1 week",[13],"Drug: GLP-1 non stop",{"label":11,"type":15,"description":11,"interventionNames":16},"ACTIVE_COMPARATOR",[17],"Drug: Stop for 1 week",[19,24],{"type":20,"name":21,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Stop for 1 week",[11],null,{"type":20,"name":25,"description":25,"armGroupLabels":26,"otherNames":23},"GLP-1 non stop",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Kuan I Sung","CONTACT","+886928139643","ioudanny520@hotmail.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":38,"countryCode":40,"cosmosGeoPoint":23,"geoPoint":23,"contacts":41},"FJUH","RECRUITING","New Taipei City","Taiwan","24352","TW",[42],{"name":29,"role":30,"phone":43,"phoneExt":23,"email":44},"0928139643","danny520julia@gmail.com",{"type":46,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100649490","phase-3-discontinuation-one-week-recommendations-for-glp-1-receptor-agonists-prior-to-esophagogastroduodenoscopy-100649490",false,"NCT07736911","Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.","Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).\n\n  * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.\n  * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.\n  * Age between 18 and 70 years.\n  * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n  * Provision of written informed consent.\n  * Outpatient status.\n  * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD.\n\nExclusion Criteria:\n\n* • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).\n\n  * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).\n  * Any other condition deemed inappropriate by the treating physician.\n  * Body mass index (BMI) \\> 40 kg\u002Fm².\n  * Liver cirrhosis.\n  * Parkinson's disease.\n  * Dementia.\n  * Use of tricyclic antidepressants or opioid medications for more than 3 months.","ALL","18 Years","90 Years",{"count":58,"type":59},140,"ESTIMATED","INTERVENTIONAL",[62],"PHASE3","This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.",[65],"GLP-1","2026-07-26",{"date":68,"type":69},"2026-07-30","ACTUAL",{"date":71,"type":69},"2026-06-01",{"date":73,"type":59},"2030-06",{"name":5,"class":6},1]